- Home
- Who We Are
About Us
Qu Biologics has attracted a team of life sciences professionals who are leaders in their respective fields.
- What We Do
What We Do
Qu Biologics’ SSIs restore innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease.
- Clinical Trials
Clinical Trials
Investigational treatment QBECO SSI is an immunotherapy aimed at restoring normal immune function to reverse the chronic inflammation underlying Crohn’s disease.
- Partner With Us
Partner With Us
To gain a better understanding of the root causes of disease and the potential benefits of novel immunotherapies, Qu Biologics has a number of university research collaborations.
- Qu In The News
- Careers
Careers
Join a team of innovators who have a passion to make a difference. In a short time, our ambitious team has achieved a number of major milestones and we have many big goals ahead.
- Contact Us
In the press
News Articles
- COVID-19 and Qu Biologics’ goal to prevent future pandemics – The Goods hosted by Dahlia Kurtz on CFRA 580 AM Radio, July 11, 2020
- Is a Cure for IBD Close? – GI Society’s Inside Tract, July 14, 2017
- Immune Therapy Shows Response and Remission in Crohn’s Patients, Study Finds – IBD News Today, April 28, 2017
- Qu Biologics Developing CDx for Immunomodulator Drug to Treat Inflammatory Bowel Disease – GenomeWeb, March 23, 2017
- Immunotherapy Encompasses more than Immuno-oncology – Genetic Engineering and Biotechnology New, November 21, 2016
- Genome BC backs Qu Biologics study for ulcerative colitis – Biotechnology Focus, April 11, 2016
- Canadian ventures focus on new immunotherapies for cancer – Nikkei Biotech Online, January 29, 2016
- Life-altering treatment – Truro Daily News, November 14, 2015
- Freeman cancer recovery fuels desire to help – The Londoner, February 9, 2015
- Body, Mind & Spirit Radio Show – CHRW 94.9 FM Radio, January 21, 2015
- Crohn’s Trial Looking For Participants – Listen To Your Gut, December 8, 2014
- Qu Biologics Seeking Crohn’s Disease Patients – Inside Tract, Issue 191, Nov 2014
- Qu Biologics Using Social Media for Good – Insights, Summer 2014
- Hedging Bets with Drug Discovery Platforms – Life Sciences 2014, Mar 2014
- New Crohn’s disease treatment trial now open to those in the U.S. – EmaxHealth, Feb 18, 2014
- New Research Trial Underway for Crohn’s Disease – Alive Magazine, Feb 17, 2014
- Bacteriology, A Caring Culture – Nature Outlook, Dec 19, 2013
- Top Health Industry Issues of 2014 – PwC Global Report, Dec 2013
- The battle against Crohn’s disease – Biotechnology Focus, Jun 13, 2013
- Vancouver company begins revolutionary new trial to treat Crohn’s disease – Global BC News, May 31, 2013
- Sky’s the Limit, London Telecom Millionaire Turns His Attention to Philanthropy, Medical Research – London Free Press, May 18, 2013
- Fighting cancer and other diseases naturally with immune-stimulators – Vancouver Sun, May 9, 2013
- Treating Cancer with Site Specific Immunotherapy – Cancer Strategies Journal, Spring 2013
Videos and other media
- Qu Biologics’ SSI Investigational Treament for Crohn’s Disease and Ulcerative Colitis
- Qu Biologics’ SSI Investigational Treatments for Cancer
- About Qu Biologics’ Site Specific Immunomodulators and How They May Work
- About Qu Biologics’ Founder & CEO, Dr. Hal Gunn
Awards